CART prescription trends in a prospective HIV cohort in rural Tanzania from 2007 to 2011

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Franzeck, Fabian C ^a,d   Letang, Emilio ^a,c,d   Mwaigomole, Geoffrey ^b   Jullu, Boniphace ^b   Glass, Tracy R ^a,d   Nyogea, Daniel ^a,b   Hatz, Christoph ^a,d   Tanner, Marcel ^a,d   Battegay, Manuel ^d,e  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b IFAKARA HEALTH INSTITUTE   (Tanzania)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d UNIVERSITY OF BASEL   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Africa; AIDS; cART; Combination; HIV; Regimen; Stavudine

Indexed keywords

ABACAVIR PLUC DIDANOSINE PLUS LOPINAVIR PLUS RITONAVIR; ABACAVIR PLUC DIDANOSINE PLUS RITONAVIR PLUS SAQUINAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; STAVUDINE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CHOICE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PROSPECTIVE STUDY; RURAL POPULATION; TANZANIA; TREND STUDY; CD4+ T LYMPHOCYTE; CYTOLOGY; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG PRESCRIPTIONS; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RURAL POPULATION; STAVUDINE; TANZANIA;

EID: 84896710204     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-90     Document Type: Article

References (17)

1. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents, 2010 revision. 2010, http://www.who.int/entity/hiv/pub/arv/adult2010/en/index.html, World Health Organization.
2. van Oosterhout JJ, Mallewa J, Kaunda S, Chagoma N, Njalale Y, Kampira E, Mukaka M, Heyderman RS. Stavudine toxicity in adult longer-term ART patients in Blantyre, Malawi. PLoS One 2012, 7(7):e42029. 10.1371/journal.pone.0042029, 3406059, 22848696.
3. Forna F, Liechty CA, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, Brooks JT, Weidle PJ. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007, 44(4):456-462. 10.1097/QAI.0b013e318033ffa1, 17279048.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2004, http://aidsinfo.nih.gov/guidelines, Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services.
5. Médecins sans frontières Campaign for access to essential medicine, untangling the web of antiretroviral price reductions. http://utw.msfaccess.org, Médecins sans frontières.
6. Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, Schackman BR, Scott CA, Lu Z, Freedberg KA. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis 2010, 50(3):416-425. 10.1086/649884, 3225050, 20043752.
7. Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, et al. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr 2011, 58(3):e68-e74. 10.1097/QAI.0b013e31822a9f8d, 21765366.
8. Rosen S, Long L, Fox M, Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 2008, 48(3):334-344. 10.1097/QAI.0b013e31817ae5ef, 18545151.
9. Ministry of Health and Social Welfare of Tanzania National Guidelines for the Management of HIV and AIDS. 2009, Dar es Salaam, Tanzania, vol. 3, http://www.nacp.go.tz/documents/nationalguideline32009.pdf, Ministry of Health and Social Welfare of Tanzania.
10. Ministry of Health and Social Welfare of Tanzania National Guidelines for the Management of HIV and AIDS. 2005, Dar es Salaam, Tanzania, vol. 2, http://www.nacp.go.tz/documents/Clinicalmanagementguidelines.pdf, Ministry of Health and Social Welfare of Tanzania.
11. Ministry of Health and Social Welfare of Tanzania National Guidelines for the Management of HIV and AIDS. 2012, Dar es Salaam, Tanzania, vol. 4, http://www.nacp.go.tz/documents/nationalguideline42012.pdf, Ministry of Health and Social Welfare of Tanzania.
12. Botswana Ministry of Health Botswana national HIV/AIDS treatment guidelines: 2012 version. 2012, http://www.hiv.gov.bw/content/2012-botswana-national-hiv-aids-treatment-guidelines, Botswana Ministry of Health.
13. Phan V, Thai S, Choun K, Lynen L, van Griensven J. Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. PLoS One 2012, 7(1):e30647. 10.1371/journal.pone.0030647, 3267733, 22303447.
14. World Health Organization Progress report 2011: Global HIV/AIDS response. Epidemic update and health sector progress towards Universal Access. 2011, http://www.who.int/hiv/pub/progress_report2011/en/index.html, World Health Organization.
15. World Health Organization A systematic review of the teratogenicity of efavirenz. 2009, http://www.who.int/hiv/topics/treatment/review_teratogenicity_efavirenz.pdf, World Health Organization.
16. Renaud-Thery F, Avila-Figueroa C, Stover J, Thierry S, Vitoria M, Habiyambere V, Souteyrand Y. Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. AIDS Res Treat 2011, 2011:749041. 3065871, 21490783.
17. Eholie SP, Aoussi FE, Ouattara IS, Bissagnene E, Anglaret X. HIV treatment and care in resource-constrained environments: challenges for the next decade. J Int AIDS Soc 2012, 15(2):17334. 3494167, 22944479.